Paliperidone overdose with delayed onset of toxicity

Annals of Emergency Medicine

Volumn 58, Issue 1, 2011, Pages 80-82

  Levine, Michael ^a,b   LoVecchio, Frank ^a,b   Tafoya, Paul ^b   Graham, Robert ^b  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b PHOENIX CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; PALIPERIDONE; VENLAFAXINE; 9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; CLINICAL EXAMINATION; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG SCREENING; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HUMAN; LABORATORY TEST; MAJOR DEPRESSION; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; PULSE RATE; SUICIDE ATTEMPT; TACHYCARDIA; CHEMICALLY INDUCED DISORDER; DELAYED RELEASE FORMULATION; ELECTROCARDIOGRAPHY; INTOXICATION; TIME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; ISOXAZOLES; OVERDOSE; PYRIMIDINES; TACHYCARDIA; TIME FACTORS;

EID: 80052047064     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2010.10.015     Document Type: Article

References (12)

1. Invega extended release oral tablets, paliperidone extendedrelease oral tablets [package insert]. Titusville, NJ: Janssen; 2009.
2. Governale L, Mehta H. Outpatient use of atypical antipsychotic agents in the pediatric population years 2004-2008. Food and Drug Administration Web site. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM193204.pdf. Accessed October 8, 2010.
3. de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51:80-88.
4. Yang PL, Plosker GL. Paliperidone extended release. CNS Drugs. 2007;21:417-425. (Pubitemid 46698504)
5. Hussar DA. New drugs: paliperidone, dasatinib, and decitabine. J Am Pharm Assoc. 2007;47:298-302.
6. Dlugosz H, Nasrallah HA. Paliperidone: a new extended-release oral atypical antipsychotic. Expert Opin Pharmacother. 2007;8:2307-2313. (Pubitemid 350019216)
7. Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm. 2008;65:403-413. (Pubitemid 351358341)
8. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999;60(suppl 10):5-14. (Pubitemid 29237170)
9. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extendedrelease tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmaol. 2007;27:6-14. (Pubitemid 46105757)
10. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry. 2008;16:31-43.
11. Boom S, Talluri K, Janssens L, et al. Single and multiple dose pharmacokinetics and dose proportionality of the psychotropic agents paliperidone extended release. J Clin Pharmacol. 2009;49:1318-1327.
12. Chang JP, Huang CC, Su KP. Paliperidone overdose in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:418.